Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
1999; Wiley; Volume: 39; Issue: 1 Linguagem: Inglês
10.1002/(sici)1097-0045(19990401)39
ISSN1097-0045
AutoresG.P. Murphy, B.A. Tjoa, S.J. Simmons, Haakon Ragde, M. Rogers, A. Elgamal, Gerald M. Kenny, M.J. Troychak, Michael L. Salgaller, Alton L. Boynton,
Tópico(s)Prostate Cancer Treatment and Research
ResumoThe ProstateVolume 39, Issue 1 p. 54-59 Original Article Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment G.P. Murphy, Corresponding Author G.P. Murphy Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonPacific Northwest Cancer Foundation, Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125Search for more papers by this authorB.A. Tjoa, B.A. Tjoa Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorS.J. Simmons, S.J. Simmons Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorH. Ragde, H. Ragde Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM. Rogers, M. Rogers Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorA. Elgamal, A. Elgamal Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorG.M. Kenny, G.M. Kenny Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM.J. Troychak, M.J. Troychak Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM.L. Salgaller, M.L. Salgaller Northwest Biotherapeutics, Inc., Seattle, WashingtonSearch for more papers by this authorA.L. Boynton, A.L. Boynton Department of Molecular Medicine, Northwest Hospital, Seattle, WashingtonSearch for more papers by this author G.P. Murphy, Corresponding Author G.P. Murphy Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonPacific Northwest Cancer Foundation, Northwest Hospital, 120 Northgate Plaza, Suite 205, Seattle, WA 98125Search for more papers by this authorB.A. Tjoa, B.A. Tjoa Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorS.J. Simmons, S.J. Simmons Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorH. Ragde, H. Ragde Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM. Rogers, M. Rogers Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorA. Elgamal, A. Elgamal Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorG.M. Kenny, G.M. Kenny Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM.J. Troychak, M.J. Troychak Northwest Hospital, Seattle, WashingtonSearch for more papers by this authorM.L. Salgaller, M.L. Salgaller Northwest Biotherapeutics, Inc., Seattle, WashingtonSearch for more papers by this authorA.L. Boynton, A.L. Boynton Department of Molecular Medicine, Northwest Hospital, Seattle, WashingtonSearch for more papers by this author First published: 03 March 1999 https://doi.org/10.1002/(SICI)1097-0045(19990401)39:1 3.0.CO;2-UCitations: 131AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with presumed local recurrence of prostate cancer after primary treatment failure. METHODS All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at 6-week intervals. Clinical monitoring was conducted pre-, during, and post-phase II study. Data included: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint® scan, and chest X-ray, as well as other assays to monitor cellular and humoral immune responses. RESULTS One complete and 10 partial responders were identified from this group based on National Prostate Cancer Project criteria, or on a 50% reduction of prostate-specific antigen (PSA), or on a significant resolution in lesions (biopsy-proven when possible) on ProstaScint® scan. CONCLUSIONS About 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggests that DC-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose primary treatment failed. Prostate 39:54–59, 1999. © 1999 Wiley-Liss, Inc. Citing Literature Volume39, Issue11 April 1999Pages 54-59 RelatedInformation
Referência(s)